Skip to main content
. 2020 Aug 4;9(16):e015042. doi: 10.1161/JAHA.119.015042

Figure 3. Post‐discharge follow‐up within 7, 14, and 30 days with (A) primary care physician; (B) cardiologist.

Figure 3

Monotherapy: angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors or beta‐blockers or mineralocorticoid receptor antagonist; dual therapy: (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+beta‐blockers) or (mineralocorticoid receptor antagonist+beta‐blockers) or (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+mineralocorticoid receptor antagonist); triple therapy: (beta‐blockers+angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+mineralocorticoid receptor antagonist). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitors; BB, beta‐blockers; MRA, mineralocorticoid receptor antagonist; PCP, primary care physician.